3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
6
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
13
Endometrial Neoplasms
2
Carcinoma, Ductal, Breast
2
Peritoneal Neoplasms
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma, Lobular
1
Breast Neoplasms, Male
1
Breast Neoplasm Female
1
Breast Carcinoma In Situ
1
Breast Cancer Invasive Nos
1
Advanced, Persistent, or Recurrent Endometrial Cancer
1
Interventions
Paclitaxel
15
Carboplatin
15
Taxes
9
Cisplatin
8
Topotecan
4
Docetaxel
4
Filgrastim
3
pegfilgrastim
2
paclitaxel poliglumex
2
liposomal doxorubicin
2
Methods
2
Gemcitabine
2
GEN-1
2
Etoposide
2
Erlotinib Hydrochloride
2
Educational Status
2
Early Intervention, Educational
2
Chemotherapy, Adjuvant
2
vandetanib
1
rilotumumab
1
oregovomab
1
motesanib diphosphate
1
elesclomol
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
Watchful Waiting
1
VTX-2337
1
Trabectedin
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Fallopian Tube Neoplasms
×
Letrozole
×
Clear all
NCT04111978
2025-09-29
MATAO
Swiss GO Trial Group
Phase 3
Recruiting
540 enrolled